Stand Up To Cancer (SU2C) and the American Cancer Society (ACS) recently announced the formation of a $20 million “dream team,” co-led by our very own Jedd Wolchok, chief of the Melanoma and Immunotherapeutics Service.

Funded in part by SU2C, ACS, and Bristol-Myers Squibb, the team has devised a three-pronged approach to focus on KRAS mutant lung cancer which includes: working to define the most effective therapies to target KRAS and critical related biological pathways, targeting the immune system for the treatment of KRAS mutant lung cancers, and integrating targeted therapies with immunotherapies for these lung cancers.

For more information, see the SU2C-ACS Lung Cancer Dream Team: Targeting KRAS Mutant Lung Cancers and other SU2C Scientific Research Teams.